Table 1 Characteristics of lymph node metastasis samples and melanoma patients

	Median (range)	Number of samples in category	Frequency (%)
Histology of primary		104
Unknown		14	13.5
Unclassable		10	9.6
SSM		46	44.2
NM		20	19.2
ALM		8	7.7
LMM		1	1.0
Mucosal		5	4.8
Gender		104
Male		47	45.2
Female		57	54.8
Age (years)^a	52 (25–87)	104
15–39		26	25.0
40–64		49	47.1
⩾65		29	27.9
Survival data (years)
DFS^b	1.2 (0.1–25.7)	104
OS^c	5.1 (0.8–29.3)	100
Breslow^d	2.2 (0.7–45.0)	94
≤1.00		10	10.6
1.01–2.00		30	31.9
2.01–4.00		39	41.5
>4.00		15	16.0
Ulceration^e		54
Yes		33	61.1
No		21	38.9
Lymph node involvement^f		79
0		50	63.3
⩾1		29	36.7
Treatment		74	71.2
Chemotherapy		32	30.8
Immunotherapy		20	19.2
Chemo/immunotherapy		22	21.2
No treatment		30	28.8
TYRP1/S100B^g	8.7 × 10⁻³ (5.2 × 10⁻⁶–63.6)	104

Abbreviations: ALM=acral lentiginous melanoma; DFS=disease-free survival; LMM=lentigo maligna melanoma; NM=nodular melanoma; OS= overall survival; Primary=primary lesion; S100B=S100 calcium-binding protein B; SSM=superficial spreading melanoma; TYRP1=tyrosinase-related protein 1.
^aAge at the diagnosis of primary (years).
^bDFS (years): time between primary and the first (loco)-regional metastasis.
^cOS (years): time between primary and patient death.
^dBreslow is the thickness (mm) of primary tumours as determined by histopathological examination.
^eUlceration of primary.
^fNumber of positive lymph node at primary.
^gmRNA ratio, real-time PCR determination.

Quick links

Search